Related Experiment Video
Updated: Mar 1, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Targeting the Molecular Subtypes of Triple Negative Breast Cancer: Understanding the Diversity to Progress the Field
Clinton Yam1, Sendurai A Mani2, Stacy L Moulder3
1Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Abstract:
Triple negative breast cancers (TNBCs) represent 10%-20% of primary breast cancers, and despite having greater initial sensitivity to cytotoxic chemotherapy, patients with TNBCs have higher rates of distant metastasis and a poorer prognosis compared with patients with hormone receptor positive and/or human epidermal growth factor receptor 2 positive disease. TNBC has historically been treated as a single disease entity in targeted therapy trials, but advances in gene expression profiling and other molecular diagnostic techniques over the last decade have revealed considerable biologic heterogeneity within TNBCs, including subgroups with distinct, targetable aberrations. Such molecular heterogeneity explains, in part, the disappointing performance of targeted therapeutics in unselected TNBC. Here we discuss the history of gene expression profiling in breast cancer and its application in partitioning TNBCs into subtypes that may lead to more consistent therapeutic successes in this heterogeneous disease.
Implications For Practice:
Triple negative breast cancers (TNBCs) have historically been regarded as a single entity in clinical trial design. Over the last decade, molecular characterization has revealed much heterogeneity in TNBCs, explaining in part the lackluster performance of targeted therapeutics in TNBCs as a group. In this article, we review the history of the molecular classification of breast cancer based on gene expression profiling and discuss its role in TNBCs.
Insights
Triple negative breast cancer (TNBC) is a heterogeneous disease. Gene expression profiling helps identify TNBC subtypes, leading to more effective targeted therapies and improved patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Triple negative breast cancer (TNBC) comprises 10%-20% of primary breast cancers.
- TNBC patients face poorer prognoses and higher metastasis rates than other breast cancer types.
- Historically, TNBC has been treated as a single entity, leading to challenges in targeted therapy efficacy.
Purpose of the Study:
- To review the history of gene expression profiling in breast cancer.
- To discuss the application of molecular diagnostics in partitioning TNBCs into biologically distinct subgroups.
- To highlight how understanding TNBC heterogeneity can improve targeted therapeutic success.
Main Methods:
- Review of historical gene expression profiling studies in breast cancer.
- Analysis of molecular diagnostic techniques for TNBC subtyping.
- Discussion of the impact of molecular heterogeneity on targeted therapy outcomes.
Main Results:
- Gene expression profiling has revealed significant biologic heterogeneity within TNBCs.
- Distinct TNBC subgroups with targetable aberrations have been identified.
- Molecular heterogeneity explains, in part, the limited success of targeted therapies in unselected TNBC populations.
Conclusions:
- TNBC is not a single disease but comprises diverse molecular subtypes.
- Gene expression profiling is crucial for classifying TNBCs into distinct subgroups.
- Subtyping TNBCs holds promise for developing more consistent and successful targeted therapeutic strategies.
